ArticleBMC pediatrics2025
Application of endoscopic retrograde cholangiopancreatography in children with common bile duct microdilation: a single-center retrospective cohort study of 36 cases.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesLimited data exists on endoscopic retrograde cholangiopancreatography (ERCP) for children with common bile duct microdilation (CBDM). We evaluate the benefits of ERCP applications in CBDM, with or without pancreaticobiliary maljunction (PBM).
methodsRetrospective analysis of 36 children with CBDM undergoing therapeutic ERCP. Patients were stratified by the presence (PBM group, n = 15) or absence (non-PBM group, n = 21) of PBM. Data included demographics, clinical/imaging/endoscopic findings, and post-ERCP outcomes.
resultsA total of 36 children underwent therapeutic ERCP procedures with a success rate of 100%. In the non-PBM group (n = 21), ERCP significantly reduced liver enzyme and bilirubin levels, and the bile duct diameter decreased significantly at 1 week and 3 months postoperatively. In the PBM group (n = 15), ERCP significantly reduced liver enzyme levels. During follow-up, most children showed improvement in general condition after ERCP regardless of PBM presence, with an overall treatment effectiveness rate of 77.8% (28/36). Both the frequency and severity of abdominal pain significantly decreased. The postoperative complication rate of ERCP was 19.4% (7/36). In the non-PBM group, 1 child (4.8%) underwent laparoscopic hepaticojejunostomy (LH) due to recurrent pancreatitis and new common bile duct stones after ERCP, while in the PBM group, 6 children (40%) underwent LH due to recurrent pancreatitis, bile duct stones, and bile duct dilation exceeding 10 mm.
conclusionERCP is an effective primary treatment for CBDM children without PBM and serves as a beneficial transitional intervention for those with concomitant PBM. Children with CBDM, regardless of PBM, can derive clinical benefit from ERCP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.